The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

NCT06158945 | Unknown

• 1 other identifier: soh_Med_23_10_01MS
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD

Conditions

Sickle Cell Disease

Outcome Measures

Primary Outcomes (1)

• renal affection in sickle cell patients

  assessment of urinary endothelin 1 as a marker of renal impairment in sickle cell patients

  1 year

Interventions

urinary endothelin 1 DIAGNOSTIC_TEST

assesment of endothelin 1 in urinary sample

Eligibility Criteria

• Age: 1 Year - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

The patients fulfilling all the following criteria will be included: Patients with sickle cell disease in the age range of 1-18years

You may qualify if:

• The patients fulfilling all the following criteria will be included:
• Patients with sickle cell disease in the age range of 1-18years.

You may not qualify if:

• Patients diagnosed to have coexistent renal disease before the study

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Sohag university Hospital

Sohag, Egypt

RECRUITING

Related Publications (4)

• Williams TN, Thein SL. Sickle Cell Anemia and Its Phenotypes. Annu Rev Genomics Hum Genet. 2018 Aug 31;19:113-147. doi: 10.1146/annurev-genom-083117-021320. Epub 2018 Apr 11.

  PMID: 29641911 BACKGROUND

• Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000 Aug;106(3):337-8. doi: 10.1172/JCI10726. No abstract available.

  PMID: 10930436 BACKGROUND

• Lonergan GJ, Cline DB, Abbondanzo SL. Sickle cell anemia. Radiographics. 2001 Jul-Aug;21(4):971-94. doi: 10.1148/radiographics.21.4.g01jl23971.

  PMID: 11452073 BACKGROUND

• Nath KA, Katusic ZS. Vasculature and kidney complications in sickle cell disease. J Am Soc Nephrol. 2012 May;23(5):781-4. doi: 10.1681/ASN.2011101019. Epub 2012 Mar 22.

  PMID: 22440903 BACKGROUND

MeSH Terms

Conditions

Anemia, Sickle Cell

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Esraa A Quenawey, resident

CONTACT

01026841188; esraaanwar@med.sohag.edu.eg

Alzahraa A Ahmed, professor

CONTACT

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident-pediatric department-sohag hospital university

Study Record Dates

• First Submitted: November 28, 2023
• First Posted: December 6, 2023
• Study Start: October 24, 2023
• Primary Completion: October 23, 2024
• Study Completion: October 23, 2024
• Last Updated: December 6, 2023

Record last verified: 2023-11

Locations

EG (1)